Denali Therapeutics, Inc. (DNLI)
22.96
-0.30
(-1.31%)
USD |
NASDAQ |
Sep 02, 15:43
Denali Therapeutics Cash from Investing (Quarterly) : -104.08M for June 30, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -104.08M |
| March 31, 2026 | 94.46M |
| December 31, 2025 | 20.77M |
| September 30, 2025 | 57.83M |
| June 30, 2025 | 157.94M |
| March 31, 2025 | 18.75M |
| December 31, 2024 | 172.21M |
| September 30, 2024 | 93.66M |
| June 30, 2024 | 98.57M |
| March 31, 2024 | -453.19M |
| December 31, 2023 | 73.05M |
| September 30, 2023 | 100.91M |
| June 30, 2023 | 168.07M |
| March 31, 2023 | -92.72M |
| December 31, 2022 | -127.56M |
| September 30, 2022 | 15.42M |
| June 30, 2022 | 88.63M |
| March 31, 2022 | -117.88M |
| December 31, 2021 | -40.75M |
| September 30, 2021 | -53.01M |
| Date | Value |
|---|---|
| June 30, 2021 | 97.54M |
| March 31, 2021 | -25.40M |
| December 31, 2020 | -367.34M |
| September 30, 2020 | -212.12M |
| June 30, 2020 | -30.41M |
| March 31, 2020 | -13.33M |
| December 31, 2019 | 42.38M |
| September 30, 2019 | 49.49M |
| June 30, 2019 | 63.88M |
| March 31, 2019 | -8.047M |
| December 31, 2018 | -61.40M |
| September 30, 2018 | 44.73M |
| June 30, 2018 | 30.53M |
| March 31, 2018 | -301.27M |
| December 31, 2017 | -95.15M |
| September 30, 2017 | |
| June 30, 2017 | |
| March 31, 2017 | |
| December 31, 2016 | -18.95M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 43.68M |
| Oncolytics Biotech, Inc. | 0.00 |
| Sangamo Therapeutics, Inc. | -0.013M |
| Sarepta Therapeutics, Inc. | -93.37M |
| Anixa Biosciences, Inc. | 0.422M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -97.00M |
| Cash from Financing (Quarterly) | 14.98M |
| Free Cash Flow | -466.26M |
| Free Cash Flow Per Share (Quarterly) | -0.6759 |
| Free Cash Flow to Equity (Quarterly) | -124.25M |
| Free Cash Flow to Firm (Quarterly) | -126.61M |
| Free Cash Flow Yield | -11.25% |